Products from BPS Bioscience require a minimum order value above 400€
Background: The WRN gene was first discovered as the gene mutated in Werner syndrome, a recessive genetic disorder characterized by segmental progeria and elevated cancer predisposition. WRN is a multifunctional enzyme with helicase and exonuclease activities and plays roles in various cellular processes crucial for the maintenance of genome stability, including DNA replication, transcription, DNA repair, and telomere maintenance. WRN depletion causes cell cycle arrest, DNA damage, mitotic defects, chromosome shattering, and apoptosis. Loss of heterozygosity involving the WRN loci at chromosome 8p11.2-p12 occurs frequently in many different cancers, pointing to its role as a tumor suppressor gene. Small molecule inhibitors of WRN can be used to induce synthetic lethality and offer a new therapeutical approach for cancer treatment.
CAS Number: 2869954-34-5
Description: HRO761 (Werner syndrome RecQ helicase-IN-1) is a potent Werner syndrome RecQ DNA helicase enzyme (WRN) inhibitor and can be used in cancer research1.
Format: Solid.
Purity: ≥90%
Storage Stability: Powder-20°C3 years 4°C2 yearsIn solvent-80°C6 months -20°C1 month
Target: WRN
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Triazolo-pyrimidine analogues for treating diseases connected to the inhibiton of werner syndrome recq helicase (wrn). WO2022249060
English
Deutsch
